抗血管内皮生长因子时代的早产儿视网膜病变管理:台湾儿童视网膜(TPR)小组的共识与推荐
台湾儿童视网膜小组由8家三级中心的11名眼科专家通过结构化流程制定早产儿视网膜病变管理共识,覆盖筛查、治疗和随访三大领域。筛查推荐沿用台湾常用标准(胎龄<32周或出生体重<1500 g)并强调需人群验证;抗VEGF药物与激光光凝均可作为1型ROP的一线治疗,需个体化决策。随访方面推荐抗VEGF治疗后延长监测,并制定持续无血管视网膜的识别与监测标准。
要点
- 筛查推荐胎龄<32周或出生体重<1500 g,但强调需基于人群的验证。
- 抗VEGF药物与激光光凝均为1型ROP可接受的一线治疗,需个体化选择。
- 推荐抗VEGF治疗后延长监测,并制定持续无血管视网膜的识别与监测标准。
核心结论
- 该共识为台湾ROP管理提供更新的循证指导,涵盖传统和新兴临床挑战,旨在规范诊疗实践并保持对未来研究和临床需求变化的适应性。
研究设计与样本
- 由台湾8家三级中心的11名眼科专家组成专家组,通过关键问题制定、系统文献复习、迭代讨论和投票的结构化流程制定共识声明。
- 共识定义为采用5点Likert量表≥75%的专家投票「同意」或「强烈同意」。
主要发现
- 共识推荐涵盖筛查、治疗和随访3大领域。
- 筛查方面,专家组认可台湾常用标准——胎龄<32周或出生体重<1500 g——但强调需基于人群的验证。
- 治疗方面,抗VEGF药物和激光光凝均被认定为1型ROP可接受的一线治疗,需根据疾病特征、麻醉风险和随访能力进行个体化治疗决策。
- 共识还制定了ROP复发管理、操作规范和药物选择的指南。
- 随访方面,专家组推荐抗VEGF治疗后延长监测,并制定持续无血管视网膜的识别与监测标准,提出随访计划以发现长期眼部和神经发育并发症。
关键数值与推荐
- 筛查标准:胎龄<32周或出生体重<1500 g。
- 共识达成阈值:5点Likert量表≥75%专家投票「同意」或「强烈同意」。
- 1型ROP一线治疗:抗VEGF药物与激光光凝均可接受。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Retinopathy of prematurity (ROP) is the leading cause of childhood blindness, particularly in preterm infants. In Taiwan, the absence of national guidelines and the variability in clinical practice have highlighted the need for locally adapted consensus recommendations. METHODS: An expert panel of eleven ophthalmologists from 8 tertiary centers in Taiwan convened to develop a consensus on ROP management. Through a structured process that included key question formulation, systematic literature review, iterative discussion, and voting, the panel established consensus statements. Agreement was defined as ≥75% of panelists voting "agree" or "strongly agree" using a 5-point Likert scale. RESULTS: Consensus recommendations were developed across 3 major domains: screening, treatment, and follow-up. For screening, the panel endorsed criteria commonly used in Taiwan-gestational age <32 weeks or birth weight <1500 g-but emphasized the need for population-based validation. Both antivascular endothelial growth factor (VEGF) agents and laser photocoagulation were recognized as acceptable first-line treatments for type 1 ROP, with individualized treatment decisions based on disease characteristics, anesthesia risk, and follow-up capacity. Guidelines were also established for the management of ROP reactivation, procedural protocols, and agent selection. For follow-up, the panel recommended extended surveillance after anti-VEGF therapy and outlined the criteria for identifying and monitoring persistent avascular retina. Follow-up schedules were proposed to detect long-term ocular and neurodevelopmental complications. CONCLUSIONS: This consensus provides updated evidence-based guidance for ROP care in Taiwan, addressing both traditional and emerging clinical challenges. These recommendations aim to standardize care practices while remaining adaptable to future research and evolving clinical needs.
引用
- Lai TT, Chen YC, Chi SC, et al. Management of Retinopathy of Prematurity in the Anti-VEGF Era: Consensus and Recommendations From the Taiwan Pediatric Retina (TPR) Group. Am J Ophthalmol. 2025. PMID: 41043633. doi:10.1016/j.ajo.2025.09.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。